| Entry |
|
|---|
| Name |
Saxagliptin hydrochloride;
Onglyza (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C18H25N3O2. HCl
|
|---|
| Exact mass |
351.1714
|
|---|
| Mol weight |
351.8709
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02925 CYP3A5 substrate
|
|---|
| Remark |
| Product (DG00119): | D09753<JP> D10262<US> |
| Product (mixture): | D10263<US> D10826<US> |
|
|---|
| Efficacy |
Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) inhibitor |
|---|
| Comment |
Treatment of type II diabetes mellitus and metabolic syndrome
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04974 | Protein digestion and absorption |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP3A5 [HSA: 1577]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH03 Saxagliptin
D10262 Saxagliptin hydrochloride <US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Saxagliptin
D10262 Saxagliptin hydrochloride
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
DG00119 Saxagliptin
D10262 Saxagliptin hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00119 Saxagliptin
D10262 Saxagliptin hydrochloride
DG02925 CYP3A5 substrate
DG00119 Saxagliptin
D10262 Saxagliptin hydrochloride
Drug classes [BR:br08332]
Antidiabetic agent
DG01601 DPP-4 inhibitor
D10262 Saxagliptin hydrochloride
DG02044 Hypoglycemic agent
D10262 Saxagliptin hydrochloride
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Peptidyl-peptidases
DPP4 (CD26)
D10262 Saxagliptin hydrochloride <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10262
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10262
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10262
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10262
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01601 DPP-4 inhibitor
DG00119 Saxagliptin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00119 Saxagliptin
DG02925 CYP3A5 substrate
DG00119 Saxagliptin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 24
1 C1z C 19.3200 -17.4300
2 C1x C 18.6200 -18.8300
3 C1y C 18.6200 -20.0900
4 C1y C 18.1300 -19.3900
5 C1z C 20.4400 -19.3900
6 C1x C 17.0800 -20.5100
7 C1x C 19.7400 -21.0700
8 C1x C 18.1300 -18.0600
9 C1x C 19.3200 -20.0200
10 C1x C 20.4400 -18.0600
11 C1c C 19.3200 -16.0300
12 C5a C 20.5100 -15.4000
13 N1a N 18.1300 -15.4000
14 N1y N 21.7000 -16.0300
15 O5a O 20.5100 -14.0000
16 C1y C 22.1200 -17.3600
17 C1y C 23.5200 -17.3600
18 C1x C 23.9400 -15.9600
19 C1y C 22.7500 -15.2600
20 C3b C 22.7500 -13.8600
21 N3a N 22.7500 -12.4600
22 O1a O 21.7700 -19.3900
23 C1x C 22.8200 -18.5500
24 X Cl 27.2300 -19.8100
BOND 27
1 1 2 1
2 2 3 1
3 8 4 1
4 4 9 1
5 9 5 1
6 5 10 1
7 10 1 1
8 1 8 1
9 3 6 1
10 3 7 1
11 4 6 1
12 5 7 1
13 1 11 1
14 11 12 1
15 11 13 1 #Down
16 12 14 1
17 12 15 2
18 14 16 1
19 16 17 1
20 17 18 1
21 18 19 1
22 14 19 1
23 19 20 1 #Down
24 20 21 3
25 5 22 1
26 17 23 1
27 23 16 1
|
|---|
